RELMADA THERAPEUTICS, INC.
Clinical-stage biotech developing therapies for bladder cancer and compulsive disorders.
RLMD | US
Overview
Corporate Details
- ISIN(s):
- US75954H1005 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 2222 PONCE DE LEON BLVD. 3RD FLOOR, 33134 CORAL GABLES
- Website:
- https://www.relmada.com/
Description
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company developing novel therapies. The company's lead program is NDV-01, a sustained-release, intravesical formulation of gemcitabine and docetaxel for the treatment of non-muscle invasive bladder cancer. The formulation is designed for gradual drug release over 10 days to enhance local exposure and minimize systemic toxicity. Relmada's pipeline also includes Sepranolone, which is being developed for compulsive disorders. Following positive proof-of-concept data in Tourette’s syndrome, the company is planning a Phase 2 study of Sepranolone in Prader-Willi Syndrome, a rare genetic disorder.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-04 13:00 |
8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
|
English | ZIP • 34.7 MB |
Automate Your Workflow. Get a real-time feed of all RELMADA THERAPEUTICS, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for RELMADA THERAPEUTICS, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for RELMADA THERAPEUTICS, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
